In the SELECT trial — a double-blind RCT of 17,604 non-diabetic adults with obesity or overweight and established cardiovascular disease — semaglutide 2·4 mg once weekly reduced the 3-point MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% over a mean 40-month follow-up (HR 0·80; 95% CI 0·72–0·90; p<0·001).
How Was the SELECT Trial Structured and Which Patients Were Included?
SELECT (NCT03574597) enrolled 17,604 adults aged 45 or older with a BMI of 27 or above and established atherosclerotic cardiovascular disease but no prior or current diabetes diagnosis. Participants were randomised 1:1 to semaglutide 2·4 mg or matched placebo once weekly. Mean treatment exposure was approximately 34 months against a mean follow-up of approximately 40 months.
The trial was conducted across 804 sites in 41 countries, with the primary publication authored by Lincoff et al and appearing in the New England Journal of Medicine in November 2023. The primary composite endpoint was time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
Eligibility required a BMI of 27 or above rather than the stricter threshold of 30, deliberately capturing the overweight-with-ASCVD population. Exclusion of patients with diabetes (HbA1c of 6·5% or above at screening, or prior diagnosis) was the defining feature distinguishing SELECT from earlier GLP-1 receptor agonist CVOTs such as LEADER and SUSTAIN-6.
What Were the Primary Endpoint Results and Hazard Ratio?
A primary MACE event occurred in 569 of 8,803 patients (6·5%) in the semaglutide group versus 701 of 8,801 patients (8·0%) in the placebo group, yielding a hazard ratio of 0·80 (95% CI 0·72–0·90; p<0·001). This 20% relative risk reduction was consistent across pre-specified subgroups and met the superiority threshold.
The Kaplan-Meier curves for the primary endpoint began diverging within the first six months of treatment and continued to separate throughout the observation period. This early-onset pattern suggests a mechanism that is not purely structural or anatomical. The number needed to treat over the trial's mean follow-up was approximately 67.
The trial was event-driven, requiring a pre-specified minimum of 1,225 primary endpoint events, and the final analysis was triggered at 1,270 events. The upper confidence interval bound of 0·90 remained well below the pre-specified superiority margin, confirming robust statistical significance.
How Did Individual MACE Components and Secondary Endpoints Perform?
Nonfatal myocardial infarction drove the composite signal most strongly, with an HR of 0·72 (95% CI 0·61–0·85), representing a 28% relative reduction. Cardiovascular death showed a directionally consistent HR of 0·85 (95% CI 0·71–1·01) that did not reach individual statistical significance. All-cause mortality was reduced (HR 0·81; 95% CI 0·71–0·93).
Heart failure outcomes — a pre-specified secondary composite of hospitalisation for heart failure or urgent heart failure visit — were also reduced (HR 0·82; 95% CI 0·71–0·96). This finding is of particular mechanistic interest given that the enrolled population included patients with prior heart failure at baseline.
The all-cause mortality reduction is notable because CVOTs in diabetic populations have rarely demonstrated significant all-cause mortality benefit. SELECT's non-diabetic population may have had a different competing-risk profile that allowed this signal to emerge. The hierarchical testing procedure preserved type I error control across the primary and key secondary endpoints.
Is the Cardiovascular Benefit Independent of Weight Loss Magnitude?
Pre-specified and post-hoc analyses published in JACC (2024) demonstrated that semaglutide's MACE reduction was not statistically mediated by the degree of weight loss achieved. Patients who lost less than 5% body weight showed similar relative risk reductions to those who lost 15% or more. C-reactive protein declined with semaglutide independent of weight-loss magnitude, implicating direct anti-inflammatory receptor signalling.
This weight-loss independence finding has significant mechanistic implications. GLP-1 receptors are expressed on cardiomyocytes, vascular endothelial cells, and macrophages, providing plausible direct cardioprotective pathways beyond adiposity reduction. Semaglutide's attenuation of NF-kB-mediated inflammatory signalling and oxidative stress in vascular tissue have been proposed as contributing mechanisms.
The JACC substudy analysis used mediation analysis to estimate that weight loss accounted for a minority fraction of the observed MACE reduction. Blood pressure lowering, lipid changes, and CRP reduction each contributed partial independent signals. This pattern suggests the cardiovascular benefit is mechanistically multifactorial rather than attributable to any single pathway.
Was the Benefit Consistent Across Pre-Specified Subgroups?
The primary endpoint hazard ratio was directionally consistent across all major pre-specified subgroups, including age strata, sex, BMI category, geographic region, prior myocardial infarction, prior stroke, and baseline renal function. No subgroup demonstrated a statistically significant interaction with treatment assignment, supporting the generalisability of the primary result.
A 2025 population-level analysis (Nanna et al) confirmed that patients with overweight (BMI 27–30) derived the same relative risk reduction as those with obesity (BMI 30 or above). Patients with prior heart failure at baseline also showed consistent benefit, reinforcing the heart failure secondary endpoint signal.
Baseline HbA1c strata within the non-diabetic range showed no significant interaction, addressing whether patients with prediabetes drove the effect. The Lancet subgroup publication (Deanfield et al, 2024) found no evidence of effect modification by prior statin use or baseline LDL-C. These analyses collectively support broad applicability of the primary finding.
What Safety Signals Were Identified in SELECT?
Serious adverse events were numerically lower in the semaglutide group (33·4% vs 36·4%). Gastrointestinal events — nausea, vomiting, diarrhoea — were more frequent with semaglutide (nausea 19·9% vs 8·1%) and were the primary driver of treatment discontinuation (16·6% vs 8·2%). No excess pancreatic, thyroid, or retinal adverse signals were identified at the trial's follow-up duration.
Gallbladder-related events occurred more frequently in the semaglutide arm (2·8% vs 2·3%), consistent with the known class effect of GLP-1 receptor agonists on bile acid kinetics and gallbladder motility. Acute pancreatitis rates were low and numerically balanced between arms.
Heart rate increased modestly with semaglutide (mean plus 1·3 bpm), a class effect previously documented across GLP-1 receptor agonists. This modest elevation did not translate into excess atrial fibrillation or other arrhythmic events in the trial data. Injection-site reactions were infrequent and did not differ meaningfully between arms.
What Is the Regulatory and Clinical Context Following SELECT?
The SELECT data supported the FDA's March 2024 approval of semaglutide 2·4 mg (Wegovy) for cardiovascular risk reduction in adults with established CVD and obesity or overweight — the first weight-management agent to receive a cardiovascular indication in the United States. The EMA similarly updated the Wegovy label to include this cardiovascular indication.
These regulatory actions represent a categorical shift: semaglutide 2·4 mg is now positioned as a secondary cardiovascular prevention therapy in a non-diabetic population, not merely as a weight-management agent. This framing carries significant implications for prescribing guidelines and payer coverage decisions across health systems.
Ongoing investigations are examining whether the cardiovascular benefit extends to primary prevention populations, lower BMI thresholds, and patients with heart failure with preserved ejection fraction. SELECT's event-driven design and non-diabetic enrolment criterion establish it as a methodological benchmark for future GLP-1 receptor agonist cardiovascular outcomes trials. How Much Does Semaglutide 2.4 mg Reduce Major Cardiovascular Events in Non-Diabetic Patients With Established CVD in 2026? What Does 2026 Research Reveal About Semaglutide Therapy Trends and Strategies to Improve Its Bioavailability? What Does 2026 Research Show About Semaglutide's Role in Metabolic Medicine?